Trial Profile
Pivotal phase III trial of TOL 101 vs thymoglobulin for the prevention of acute renal transplant rejection.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2012
Price :
$35
*
At a glance
- Drugs TOL 101 (Primary) ; Antithymocyte globulin
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- 02 Nov 2012 New trial record